HISKY MED – Series B Financing
HISKY MED closed a $15 million series B financing round from Legend Capital, 3E Bioventures and Chang’an Capital with Haoyue Capital as the exclusive financial advisor.
HISKY MED is a rapidly growing company specialized in developing, manufacturing and marketing of high-tech medical equipment for non-invasive liver diagnosis. Its self-developed non-invasive liver fibrosis diagnostic system, FibroTouch, is capable of making quantitative detection and assessment of liver fibrosis and hepatic steatosis with low frequency shear wave technology. -- ITJuzi
Partnred with Tsinghua University, HISKY MED owns over 40 patents and published 70 paper. FibroTouch received experts acknowledge at The 2016 Asian Pacific Association for the Study of the Liver.
Legend Capital is a leading early-stage venture capital and expansion-stage growth capital managing several USD and RMB funs with a total $4.3 billion. Legend Capital accomplished 40 exits through M&A.